Sadeh Menachem, Fellig Yakov, Dabby Ron
Neurology, Edith Wolfson Medical Center, Holon, Tel Aviv, Israel.
Pathology, Hadassah Medical Center, Jerusalem, Jerusalem, Israel.
BMJ Neurol Open. 2024 Nov 14;6(2):e000892. doi: 10.1136/bmjno-2024-000892. eCollection 2024.
Late-onset sporadic nemaline myopathy (SLONM) is a rare, treatable or potentially life-threatening muscle disorder that typically manifests late in life and is characterised by the presence of nemaline rods within muscle fibres, serving as the hallmark of the disease and the key to diagnosis.
We report a case of an elderly patient with subacute onset of severe weakness affecting the upper and lower limbs, neck extensors and abdominal muscles. A comprehensive laboratory workup was performed.
Muscle biopsies showed nonspecific myopathic changes without inflammation, and electron microscopy did not reveal rods or aggregates. The laboratory workup was unremarkable except for the detection of monoclonal gammopathy of undetermined significance. Steroid treatment was ineffective; however, there was a notable positive response to intravenous immunoglobulins. The neurological findings, subacute course, normal creatine kinase levels, presence of monoclonal gammopathy of unknown significance and responsiveness to immunoglobulin treatment but not to steroids align with the characteristics of SLONM.
We propose that the diagnosis of SLONM should be considered even in the absence of nemaline rods in muscle biopsy, and this should not impede the consideration of immunomodulatory treatment. Future progress in understanding the pathogenetic basis of SLONM may reduce reliance on pathological findings in muscle biopsies for establishing the diagnosis.
迟发性散发性杆状体肌病(SLONM)是一种罕见的、可治疗或可能危及生命的肌肉疾病,通常在生命后期出现,其特征是肌纤维内存在杆状体,这是该疾病的标志和诊断关键。
我们报告一例老年患者,亚急性起病,出现严重肌无力,累及上下肢、颈部伸肌和腹部肌肉。进行了全面的实验室检查。
肌肉活检显示非特异性肌病改变,无炎症,电子显微镜检查未发现杆状体或聚集体。实验室检查除检测到意义未明的单克隆丙种球蛋白病外无异常。类固醇治疗无效;然而,静脉注射免疫球蛋白有显著阳性反应。神经学表现、亚急性病程、肌酸激酶水平正常、存在意义不明的单克隆丙种球蛋白病以及对免疫球蛋白治疗而非类固醇治疗有反应,均符合SLONM的特征。
我们提出,即使肌肉活检未发现杆状体,也应考虑SLONM的诊断,且这不应妨碍考虑免疫调节治疗。未来在理解SLONM发病机制基础方面的进展可能会减少在诊断时对肌肉活检病理结果的依赖。